Can a diabetes drug protect kidneys when they're barely working?
NCT ID NCT07074418
First seen Jan 25, 2026 · Last updated Jun 16, 2026 · Updated 28 times
Summary
This study tests whether empagliflozin, a diabetes medicine, can reduce protein leakage in urine and help protect the kidneys in people with very advanced chronic kidney disease (eGFR between 10 and 20). About 34 adults with type 2 diabetes will take either empagliflozin or a placebo for 6 weeks each. The goal is to see if the drug still works to lower protein in urine even when kidney function is severely reduced.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Nice - Hôpital Pasteur 2
Nice, Alpes-Maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.